FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165307683> ?p ?o ?g. }

• W3165307683 endingPage "892" @default.
• W3165307683 startingPage "892.1" @default.
• W3165307683 abstract "Background: The epidemiology of COVID19 among patients with AIIRD may be influenced by a dysregulated immune system, immunosuppressive therapies and behavioral patterns. Data regarding the epidemiology of COVID19 among patients with AIIRD is scarce. Objectives: To assess the pattern of COVID19 pandemic among patients with AIIRD compared to the general population in Israel Methods: At the beginning of the COVID-19 pandemic, we established a national registry of patients with AIIRD, diagnosed with COVID-19, based on voluntary reporting by the treating rheumatologist. All the members of the Israeli Society of Rheumatology were encouraged to participate and repeatedly reminded to report any new cases. Rheumatology centers from 11 hospitals from the Northern and Central part of Israel participated in this study. The registry included demographic data, AIIRD diagnosis and duration, systemic organ involvement, co-morbidities, treatment (conventional synthetic disease modifying drugs (csDMARDs), biologic/targeted (b/ts) DMARDs, corticosteroids use, dose and treatment duration, date of COVID19 diagnosis, severity of the viral disease and complications, duration of hospitalization, if required, treatment for COVID 19, laboratory results and outcome. The diagnosis of COVID 19 was made by a positive SARS CoV2 PCR. The indications for SARS CoV2 PCR testing in Israel comprise clinical symptoms or exposure to a confirmed close contact. Severe illness was defined by SpO 2 <94% in room air, respiratory rate of >30 breaths/min, PaO 2 /FiO 2 <300 mm Hg, or lung infiltrates >50% on chest imaging. The epidemiological data regarding the number of COVID19 confirmed patients, the number of severe cases and the rate of mortality among the general population per day and per week, were extracted from the data dashboard of the Israeli Ministry of Health. We analyzed data from 02.2020 to 15.01.2021. Results: During the study period we experienced 3 waves of COVID 19 pandemic. The governmental management of COVID19 spread, at the beginning of the pandemic, included inforcement of severe travel restrictions and social distancing, followed eventually by a preventive lockdown, in spite of the relatively low number of cases. Easing of the restrictions, lifting the travel ban, opening of the commerce and schools led to 2 much more severe waves, which triggered 2 new lockdowns. Up to January 2021, 549763 Israelis had confirmed COVID19, 30% of whom had severe disease, 0.84% died (30% of the patients with severe disease). We identified 190 AIIRD patients (mean(SD) age 52(18), 30% males) who had confirmed COVID19. The weekly incidence curve of patients with rheumatic diseases correlated with the curve of the general population (Figure 1). Sixty-one % of the patients with AIIRD received csDMARDs, 41% were on b/tsDMARDs, 39% on chronic corticosteroids, 12% on ≥10mg prednisone. Forty-seven% of patients required hospitalization, 20% had severe COVID19. Sixteen patients (42% of patients with severe COVID19) (mean(SD), median age 64.7(15.4),67)) died (systemic sclerosis-4 patients, rheumatoid arthritis – 6, systemic lupus erythematosus – 2, antiphospholipid syndrome-2, granulomatous polyangiitis -1, polymyalgia rheumatica-1). The AIIRD was active in 56% of them, 50% received csDMARDs, none of them were on b/tsDMARDs, 31% received chronic prednisone>10 mg. All patients who died had at least 2 comorbidities. Conclusion: The pattern of spread of COVID19 in AIIRD patients is similar to the general population despite repeated mass media alerts for enhanced social distancing for elderly and immune suppressed patients. The disease tends to be more severe with enhanced mortality, especially in those with active AIIRD disease and organ involvement (lungs, heart, renal), older age and co-morbidities. A reporting bias cannot be excluded. Figure 1. Acknowledgements: Both first authors contributed equally to the manuscript. Disclosure of Interests: None declared." @default.
• W3165307683 created "2021-06-07" @default.
• W3165307683 creator A5001813193 @default.
• W3165307683 creator A5003506058 @default.
• W3165307683 creator A5006348084 @default.
• W3165307683 creator A5007376024 @default.
• W3165307683 creator A5009083689 @default.
• W3165307683 creator A5017010569 @default.
• W3165307683 creator A5019437411 @default.
• W3165307683 creator A5034093805 @default.
• W3165307683 creator A5044424002 @default.
• W3165307683 creator A5048407127 @default.
• W3165307683 creator A5048752246 @default.
• W3165307683 creator A5050621515 @default.
• W3165307683 creator A5055749587 @default.
• W3165307683 creator A5055829022 @default.
• W3165307683 creator A5056671146 @default.
• W3165307683 creator A5063470045 @default.
• W3165307683 creator A5063470054 @default.
• W3165307683 creator A5064622710 @default.
• W3165307683 creator A5070813771 @default.
• W3165307683 creator A5076190931 @default.
• W3165307683 creator A5076592956 @default.
• W3165307683 creator A5076827392 @default.
• W3165307683 creator A5082814481 @default.
• W3165307683 date "2021-05-19" @default.
• W3165307683 modified "2023-09-23" @default.
• W3165307683 title "POS1217 THE PATTERN OF COVID 19 PANDEMIC AMONG PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES (AIIRD)" @default.
• W3165307683 doi "https://doi.org/10.1136/annrheumdis-2021-eular.2581" @default.
• W3165307683 hasPublicationYear "2021" @default.
• W3165307683 type Work @default.
• W3165307683 sameAs 3165307683 @default.
• W3165307683 citedByCount "0" @default.
• W3165307683 crossrefType "journal-article" @default.
• W3165307683 hasAuthorship W3165307683A5001813193 @default.
• W3165307683 hasAuthorship W3165307683A5003506058 @default.
• W3165307683 hasAuthorship W3165307683A5006348084 @default.
• W3165307683 hasAuthorship W3165307683A5007376024 @default.
• W3165307683 hasAuthorship W3165307683A5009083689 @default.
• W3165307683 hasAuthorship W3165307683A5017010569 @default.
• W3165307683 hasAuthorship W3165307683A5019437411 @default.
• W3165307683 hasAuthorship W3165307683A5034093805 @default.
• W3165307683 hasAuthorship W3165307683A5044424002 @default.
• W3165307683 hasAuthorship W3165307683A5048407127 @default.
• W3165307683 hasAuthorship W3165307683A5048752246 @default.
• W3165307683 hasAuthorship W3165307683A5050621515 @default.
• W3165307683 hasAuthorship W3165307683A5055749587 @default.
• W3165307683 hasAuthorship W3165307683A5055829022 @default.
• W3165307683 hasAuthorship W3165307683A5056671146 @default.
• W3165307683 hasAuthorship W3165307683A5063470045 @default.
• W3165307683 hasAuthorship W3165307683A5063470054 @default.
• W3165307683 hasAuthorship W3165307683A5064622710 @default.
• W3165307683 hasAuthorship W3165307683A5070813771 @default.
• W3165307683 hasAuthorship W3165307683A5076190931 @default.
• W3165307683 hasAuthorship W3165307683A5076592956 @default.
• W3165307683 hasAuthorship W3165307683A5076827392 @default.
• W3165307683 hasAuthorship W3165307683A5082814481 @default.
• W3165307683 hasBestOaLocation W31653076831 @default.
• W3165307683 hasConcept C107130276 @default.
• W3165307683 hasConcept C126322002 @default.
• W3165307683 hasConcept C177713679 @default.
• W3165307683 hasConcept C187212893 @default.
• W3165307683 hasConcept C198451711 @default.
• W3165307683 hasConcept C2777914695 @default.
• W3165307683 hasConcept C2779123688 @default.
• W3165307683 hasConcept C2779134260 @default.
• W3165307683 hasConcept C2908647359 @default.
• W3165307683 hasConcept C3008058167 @default.
• W3165307683 hasConcept C524204448 @default.
• W3165307683 hasConcept C71924100 @default.
• W3165307683 hasConcept C89623803 @default.
• W3165307683 hasConcept C99454951 @default.
• W3165307683 hasConceptScore W3165307683C107130276 @default.
• W3165307683 hasConceptScore W3165307683C126322002 @default.
• W3165307683 hasConceptScore W3165307683C177713679 @default.
• W3165307683 hasConceptScore W3165307683C187212893 @default.
• W3165307683 hasConceptScore W3165307683C198451711 @default.
• W3165307683 hasConceptScore W3165307683C2777914695 @default.
• W3165307683 hasConceptScore W3165307683C2779123688 @default.
• W3165307683 hasConceptScore W3165307683C2779134260 @default.
• W3165307683 hasConceptScore W3165307683C2908647359 @default.
• W3165307683 hasConceptScore W3165307683C3008058167 @default.
• W3165307683 hasConceptScore W3165307683C524204448 @default.
• W3165307683 hasConceptScore W3165307683C71924100 @default.
• W3165307683 hasConceptScore W3165307683C89623803 @default.
• W3165307683 hasConceptScore W3165307683C99454951 @default.
• W3165307683 hasIssue "Suppl 1" @default.
• W3165307683 hasLocation W31653076831 @default.
• W3165307683 hasOpenAccess W3165307683 @default.
• W3165307683 hasPrimaryLocation W31653076831 @default.
• W3165307683 hasRelatedWork W3012050440 @default.
• W3165307683 hasRelatedWork W3015785605 @default.
• W3165307683 hasRelatedWork W3022913415 @default.
• W3165307683 hasRelatedWork W3048464972 @default.
• W3165307683 hasRelatedWork W3094131409 @default.
• W3165307683 hasRelatedWork W3108471389 @default.
• W3165307683 hasRelatedWork W3139444595 @default.
• W3165307683 hasRelatedWork W3176600860 @default.

• next